Biocon gets nod for Micafungin from USFDA

04 Jun 2024 Evaluate

Biocon has received approval from the U.S. Food and Drug Administration (US FDA), for its vertically integrated, complex injectable drug product, Micafungin (50mg and 100mg vials), used as an antifungal medication to treat fungal or yeast infections. The approval further strengthens Biocon’s portfolio of vertically integrated, complex drug products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

380.70 2.90 (0.77%)
16-Feb-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1703.45
Dr. Reddys Lab 1267.45
Cipla 1357.00
Zydus Lifesciences 910.00
Lupin 2216.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×